Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity

Todd M. Hillhouse, Christina R. Merritt, Douglas A. Smith, Manuel Cajina, Connie Sanchez, Joseph H. Porter, Alan L. Pehrson

Research output: Contribution to journalArticle

Abstract

Attention impairment is a common feature of Major Depressive Disorder (MDD), and MDD-associated cognitive dysfunction may play an important role in determining functional status among this patient population. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in MDD patients, and may indirectly increase glutamate neurotransmission in brain regions classically associated with attention function. Previous non-clinical research suggests that vortioxetine has limited effects on attention. This laboratory previously found that vortioxetine did not improve attention function in animals impaired by acute scopolamine administration, using the visual signal detection task (VSDT). However, vortioxetine has limited effects on acetylcholinergic neurotransmission, and thus it is possible that attention impaired by other mechanisms would be attenuated by vortioxetine. This study sought to investigate whether acute vortioxetine administration can attenuate VSDT impairments and hyperlocomotion induced by the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. We found that acute vortioxetine administration had no effect on VSDT performance on its own, but potentiated MK-801-induced VSDT impairments. Furthermore, vortioxetine had no effect on locomotor activity on its own, and did not alter MK-801-induced hyperlocomotion. We further investigated whether vortioxetine's effect on MK-801 could be driven by a kinetic interaction, but found that plasma and brain exposure for vortioxetine and MK-801 were similar whether administered alone or in combination. Thus, it appears that vortioxetine selectively potentiates MK-801-induced impairments in attention without altering its effects on locomotion, and further that this interaction must be pharmacodynamic in nature. A theoretical mechanism for this interaction is discussed.

Original languageEnglish
Article number1024
JournalFrontiers in Pharmacology
Volume9
Issue numberSEP
DOIs
StatePublished - 13 Sep 2018

Fingerprint

Dizocilpine Maleate
Task Performance and Analysis
Locomotion
Major Depressive Disorder
Synaptic Transmission
Psychological Signal Detection
vortioxetine
Scopolamine Hydrobromide
Brain
N-Methyl-D-Aspartate Receptors
Cognition
Antidepressive Agents
Glutamic Acid

Keywords

  • Attention
  • Locomotor activity
  • MK-801
  • Visual signal detection task
  • Vortioxetine

Cite this

Hillhouse, Todd M. ; Merritt, Christina R. ; Smith, Douglas A. ; Cajina, Manuel ; Sanchez, Connie ; Porter, Joseph H. ; Pehrson, Alan L. / Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. SEP.
@article{b94f23714cc248a7ba1466dc0242ff3c,
title = "Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity",
abstract = "Attention impairment is a common feature of Major Depressive Disorder (MDD), and MDD-associated cognitive dysfunction may play an important role in determining functional status among this patient population. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in MDD patients, and may indirectly increase glutamate neurotransmission in brain regions classically associated with attention function. Previous non-clinical research suggests that vortioxetine has limited effects on attention. This laboratory previously found that vortioxetine did not improve attention function in animals impaired by acute scopolamine administration, using the visual signal detection task (VSDT). However, vortioxetine has limited effects on acetylcholinergic neurotransmission, and thus it is possible that attention impaired by other mechanisms would be attenuated by vortioxetine. This study sought to investigate whether acute vortioxetine administration can attenuate VSDT impairments and hyperlocomotion induced by the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. We found that acute vortioxetine administration had no effect on VSDT performance on its own, but potentiated MK-801-induced VSDT impairments. Furthermore, vortioxetine had no effect on locomotor activity on its own, and did not alter MK-801-induced hyperlocomotion. We further investigated whether vortioxetine's effect on MK-801 could be driven by a kinetic interaction, but found that plasma and brain exposure for vortioxetine and MK-801 were similar whether administered alone or in combination. Thus, it appears that vortioxetine selectively potentiates MK-801-induced impairments in attention without altering its effects on locomotion, and further that this interaction must be pharmacodynamic in nature. A theoretical mechanism for this interaction is discussed.",
keywords = "Attention, Locomotor activity, MK-801, Visual signal detection task, Vortioxetine",
author = "Hillhouse, {Todd M.} and Merritt, {Christina R.} and Smith, {Douglas A.} and Manuel Cajina and Connie Sanchez and Porter, {Joseph H.} and Pehrson, {Alan L.}",
year = "2018",
month = "9",
day = "13",
doi = "10.3389/fphar.2018.01024",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "SEP",

}

Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity. / Hillhouse, Todd M.; Merritt, Christina R.; Smith, Douglas A.; Cajina, Manuel; Sanchez, Connie; Porter, Joseph H.; Pehrson, Alan L.

In: Frontiers in Pharmacology, Vol. 9, No. SEP, 1024, 13.09.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vortioxetine differentially modulates MK-801-induced changes in visual signal detection task performance and locomotor activity

AU - Hillhouse, Todd M.

AU - Merritt, Christina R.

AU - Smith, Douglas A.

AU - Cajina, Manuel

AU - Sanchez, Connie

AU - Porter, Joseph H.

AU - Pehrson, Alan L.

PY - 2018/9/13

Y1 - 2018/9/13

N2 - Attention impairment is a common feature of Major Depressive Disorder (MDD), and MDD-associated cognitive dysfunction may play an important role in determining functional status among this patient population. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in MDD patients, and may indirectly increase glutamate neurotransmission in brain regions classically associated with attention function. Previous non-clinical research suggests that vortioxetine has limited effects on attention. This laboratory previously found that vortioxetine did not improve attention function in animals impaired by acute scopolamine administration, using the visual signal detection task (VSDT). However, vortioxetine has limited effects on acetylcholinergic neurotransmission, and thus it is possible that attention impaired by other mechanisms would be attenuated by vortioxetine. This study sought to investigate whether acute vortioxetine administration can attenuate VSDT impairments and hyperlocomotion induced by the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. We found that acute vortioxetine administration had no effect on VSDT performance on its own, but potentiated MK-801-induced VSDT impairments. Furthermore, vortioxetine had no effect on locomotor activity on its own, and did not alter MK-801-induced hyperlocomotion. We further investigated whether vortioxetine's effect on MK-801 could be driven by a kinetic interaction, but found that plasma and brain exposure for vortioxetine and MK-801 were similar whether administered alone or in combination. Thus, it appears that vortioxetine selectively potentiates MK-801-induced impairments in attention without altering its effects on locomotion, and further that this interaction must be pharmacodynamic in nature. A theoretical mechanism for this interaction is discussed.

AB - Attention impairment is a common feature of Major Depressive Disorder (MDD), and MDD-associated cognitive dysfunction may play an important role in determining functional status among this patient population. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in MDD patients, and may indirectly increase glutamate neurotransmission in brain regions classically associated with attention function. Previous non-clinical research suggests that vortioxetine has limited effects on attention. This laboratory previously found that vortioxetine did not improve attention function in animals impaired by acute scopolamine administration, using the visual signal detection task (VSDT). However, vortioxetine has limited effects on acetylcholinergic neurotransmission, and thus it is possible that attention impaired by other mechanisms would be attenuated by vortioxetine. This study sought to investigate whether acute vortioxetine administration can attenuate VSDT impairments and hyperlocomotion induced by the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. We found that acute vortioxetine administration had no effect on VSDT performance on its own, but potentiated MK-801-induced VSDT impairments. Furthermore, vortioxetine had no effect on locomotor activity on its own, and did not alter MK-801-induced hyperlocomotion. We further investigated whether vortioxetine's effect on MK-801 could be driven by a kinetic interaction, but found that plasma and brain exposure for vortioxetine and MK-801 were similar whether administered alone or in combination. Thus, it appears that vortioxetine selectively potentiates MK-801-induced impairments in attention without altering its effects on locomotion, and further that this interaction must be pharmacodynamic in nature. A theoretical mechanism for this interaction is discussed.

KW - Attention

KW - Locomotor activity

KW - MK-801

KW - Visual signal detection task

KW - Vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=85055184655&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.01024

DO - 10.3389/fphar.2018.01024

M3 - Article

AN - SCOPUS:85055184655

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - SEP

M1 - 1024

ER -